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ABSTRACT
Activating transcription factor 5 (ATF5) is a cellular prosurvival transcription 
factor within the basic leucine zipper (bZip) family that is involved in cellular 
differentiation and promotes cellular adaptation to stress. Recent studies have 
characterized the oncogenic role of ATF5 in the development of several different types 
of cancer, notably glioblastoma. Preclinical assessment of a systemically deliverable 
dominant-negative ATF5 (dnATF5) biologic has found that targeting ATF5 results in 
tumor regression and tumor growth inhibition of glioblastoma xenografts in mouse 
models. In this review, we comprehensively and critically detail the current scientific 
literature on ATF5 in the context of cellular differentiation, survival, and response to 
stressors in normal tissues. Furthermore, we will discuss how the prosurvival role of 
ATF5 aides in cancer development, followed by current advances in targeting ATF5 
using dominant-negative biologics, and perspectives on future research.
Basic molecular and structural properties of 
ATF5
The transcription factor ATF5 belongs to the bZip 
family of transcription factors and shares this family 
with other notable proteins such as cAMP response 
element-binding protein (CREB), Fos proto-oncogene 
(FOS), and nuclear factor erythroid-devoid 2-related 
factor 2 (NRF2). These bZip proteins are composed of 
an amphipathic leucine zipper that mediates hetero- and 
homodimerization via a coiled-coil domain along with a 
basic N-terminal portion involved in DNA binding [1, 2]. 
ATF5 is classified based on the dimerization properties 
of its leucine zipper domain into the ATF4 subfamily of 
bZip transcription factors [3]. As opposed to FOS which 
primarily heterodimerizes or CREB which primarily 
homodimerizes, ATF5 is suggested to readily hetero- and 
homodimerize with transcription factors and is perceived 
to be quite promiscuous in its binding capabilities [3], 
though little has been published on ATF5 dimerization 
partners. With this in mind, one proposed binding 
partner for ATF5 includes CCAAT/enhancer-binding 
protein-gamma (C/EBPγ) [4]. Furthermore, ATF5 shows 
pronounced sequence homology with ATF4 and shares 
similar modes of regulation and downstream effects i.e. 
both are regulated translationally via stress-responsive 
inhibitory uORFs and modulate processes involved in 
tissue development, apoptosis, and cancer [5–9]. The 
association between ATF4 and ATF5 function doesn’t stop 
there; it has been found that ATF4 is required for ATF5 
gene expression in mouse embryonic fibroblasts [6].
Transcription of the ATF5 gene results in two 
mRNA splice variants denoted ATF5α and ATF5β which 
harbor unique 5′-UTRs (5′-UTRα and 5′-UTRβ) involved 
in repression of ATF5 translation. For ATF5α, this 
repression is due to the presence of a conserved upstream 
open reading frames (uORFs) within the 5′-UTRα, thereby 
resulting in out of frame transcription regarding the ATF5 
coding DNA sequence (CDS) [6, 10]. The two ATF5 
mRNA transcripts are regulated via different mechanisms 
i.e. amino acid limitation and arsenite exposure release 
5′-UTR-mediated repression of ATF5α but not ATF5β, 
suggesting the ATF5α transcript is preferentially 
upregulated during stress. It has also been reported that 
the 5′-UTRα facilitates nonsense-mediated decay of the 
ATF5α transcript [11]. Furthermore, the ATF5α transcript 
                                                                                Review
Oncotarget84596www.impactjournals.com/oncotarget
was shown to be highly expressed late in gestation and in 
the liver of adult mice [12]. eIF2α phosphorylation, which 
generally occurs during cellular stress, drives translation 
of ATF5α mRNA by shifting ribosomal initiation towards 
the ATF5 CDS and away from the inhibitory uORF.
Control of ATF5 protein expression is governed 
through proteasomal degradation carried out by Cdc34 
and Rad6 E3 ligases [13], with which Cdc34 pathway 
for ATF5 is inhibited by cisplatin [14]. Other non-stress-
related cellular and tissue specific regulatory pathways for 
ATF5 are discussed in the section below. 
Role of ATF5 in cellular differentiation and 
tissue development
Numerous studies have reported that ATF5 plays 
a critical role in modulating differentiation pathways 
in a variety of tissues such as the brain [15], bone [16], 
liver [17], and fat [18]. Among these, ATF5-mediated 
differentiation of neural tissues has been most well 
characterized. In general, ATF5 appears to hinder 
differentiation in brain and bone tissues while conversely 
stimulating differentiation in the liver. This property 
of ATF5, to modulate tissue-specific differentiation, 
highlights the challenges in predicting ATF5 activity based 
on cell type. Because transcription factor activity is greatly 
influenced by the presence of dimerization partners, this 
indicates that there may be a wide variety of ATF5-
interacting transcription factors that can alter the function 
of ATF5 based on their tissue-specific expression profiles. 
Studies utilizing conditional knockouts to evaluate the 
role of ATF5 in modulating tissue-specific differentiation 
processes have not been performed and would provide 
valuable insight into ATF5-dependent differentiation 
processes for specific tissue types. These functions 
in tissue development, i.e. regulating the growth and 
differentiation of stem and progenitor cells, also supports 
the notion that ATF5 activity may play a role in the self-
renewal and differentiation of cancer stem cells.
Neural development
Relative to other tissue types, the role of ATF5 in the 
development of neural tissue has been widely studied. Of 
great importance are the studies utilizing ATF5 knockout 
mice. These studies showed that ATF5 knockout mice 
exhibited neonatal lethality due to a competitive suckling 
deficit [19, 20]. Further investigation revealed that ATF5 
knockout mice had significantly smaller olfactory bulbs and 
that this effect was likely related to reduced proliferation 
of neural progenitors of the subventricular zone. This 
highlights the importance of ATF5 in neural development 
and suggests ATF5 plays a significant role in modulating 
the growth and differentiation of neural progenitors.
Early studies showed that in PC12 primitive neural 
crest cells, ATF5 gene transcripts were downregulated 
more than 25-fold upon NGF-stimulated differentiation 
[21]. Further investigation by Angelastro et al. revealed 
that ATF5 is highly expressed by neural progenitor cells 
in the ventricular zone of the developing rat brain and that 
ATF5 maintains neural progenitors in the cell cycle [15, 
22]. Angelastro et al. also showed that ATF5 mediates 
differentiation of neural progenitors in developing rat 
brain telencephalic cell cultures and that ATF5 represses 
neurite outgrowth of PC12 cells, which is thought to be 
via repression of cAMP response element transactivation. 
In addition to the hindrance of neuronal differentiation by 
ATF5, it was shown that ATF5 represses the differentiation 
of neural progenitors into oligodendrocytes and astrocytes 
in vitro and in vivo [22, 23]. Lastly, Lee et al. reported that 
ATF5 promotes sonic hedgehog-mediated proliferation 
of cerebellar granule neural progenitor cells, thereby 
indicating that ATF5 plays an important role in neural 
progenitors outside the cerebral cortex [24]. These findings 
indicate that ATF5 represses differentiation of neural 
progenitors and that downregulation of ATF5 is required 
for differentiation of neural progenitors into astrocytes, 
neurons, and oligodendrocytes. While this is true, later 
studies revealed that mature neurons can upregulate ATF5 
in response to ER stress and that this has a neuroprotective 
role against apoptotic cell death [25]. This also suggests 
that ATF5 possesses functional roles in promoting the 
survival of neurons. This raises questions about potential 
off-target toxicities that may be associated with targeting 
ATF5 for anticancer therapies. With this in mind, studies 
administering dnATF5 to animals have not resulted in 
toxicity to normal adult organs and tissues, including the 
CNS [26, 27].
Further studies intended to define the role of 
ATF5 in the differentiation of neuroglial cell types such 
as oligodendrocytes and astrocytes. Indeed, Wang et al. 
showed that ATF5 mediates the survival and differentiation 
of olfactory sensory neurons (OSNs) using ATF5 knockout 
mice [20]. Wang et al. reported that ATF5 knockout mice 
exhibited a substantial increase in mortality at the neonatal 
stage and that a faulty olfactory system was responsible 
for this effect. Specifically, Wang et al. identified that 
ATF5 was highly expressed in mature OSNs and that this 
expression was required for differentiation, critical for 
survival, and activated OSN-specific gene expression of 
mature OSNs. Various publications further support this 
role for ATF5 by showing ATF5 is significantly expressed 
in the olfactory epithelium and that ATF5 knockout mice 
possess markedly smaller olfactory bulbs compared to 
wild type mice [10, 16, 17]. These findings are consistent 
with the accepted prosurvival and antiapoptotic role of 
ATF5 that is observed in other cell types. Furthermore, 
the function of ATF5 in promoting differentiation of 
OSNs is contrary to the differentiation suppressor role 
of ATF5 in neural progenitor cells of the cerebral cortex 
and cerebellum. In addition, this suggests that neonatal 
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lethality in mice may be overcome by giving special 
attention to competitive suckling deficits that arise from 
an olfactory defect.
Hepatic differentiation
Interestingly, ATF5 is most highly expressed in the 
liver and possesses an opposing role in the differentiation 
of hepatocytes relative to neural progenitors [12]. This 
effect was first identified by Du et al. upon analyzing 
differentially expressed genes in primary and fetal human 
hepatocytes where ATF5 was seen to be significantly 
upregulated in mature hepatocytes [28]. Du et al. also 
showed that ATF5 could perform the role of maturation 
factor in lineage-reprogrammed human embryonic 
fibroblasts. Work following this study was able to show 
that ATF5 also acts as a maturation factor in induced 
pluripotent stem cells [17]. Lastly, ATF5 has been shown 
to cooperate with the nuclear receptor constitutive 
androstane receptor (CAR) to transactivate cytochrome 
P450 2B6 (CYP2B6), giving evidence that ATF5 mediates 
transcription of proteins in the liver associated with 
specialized hepatic function [29]. Overall, these findings 
indicate that ATF5 is upregulated upon differentiation of 
hepatocytes as opposed to ATF5-mediated differentiation 
in neural lineages. 
Osteogenesis
Initial studies by Leong et al. with adipose-derived 
stem cells (ADSCs), i.e. adipose-derived mesenchymal 
stem cells, found that upon osteogenic differentiation these 
ADSCs consistently downregulated ATF5 [16]. Leong et 
al. also showed that ATF5 knockdown sensitized ADSCs 
to osteogenic stimulation. While these findings provide 
limited evidence to supporting the repressive role of ATF5 
in osteogenic differentiation, they highlight the functional 
role of ATF5 in modulating the differentiation of a diverse 
range of tissue types.
Adipogenesis
The finding that ATF5 modulates osteogenesis 
in ADSCs led to studies investigating the role of ATF5 
in adipogenesis due to the known overlap between 
osteogenic and adipogenic signaling pathways e.g. 
insulin-like growth factor (IGF) signaling. Using a yeast 
two-hybrid assay supplemented with a pulldown assay, 
Zhao et al. reported that ATF5 physically interacts with 
C/EBPβ to bind to and activate the C/EBPα promoter, 
and that this interaction is mediated by p300 [18]. In 
addition, Zhao et al. showed that knockdown of ATF5 
inhibited adipocyte differentiation through the effect of 
ATF5 on C/EBPα. Interestingly, Zhao et al. reported that 
ATF5 expression correlated with obesity in both mice and 
humans. Overall, these findings give evidence for ATF5-
mediated adipogenesis and even suggest a potential role 
for ATF5 in obesity.
Role of ATF5 in protein homeostasis 
(Proteostasis) and the integrated stress response 
(ISR)
ATF5, like other ATF-family transcription factors 
such as ATF4 and ATF6, mediates transcriptional 
responses to cellular stressors. Cellular stress responses 
reported to be influenced by ATF5 activity include the 
cytosolic heat shock response, the ER unfolded protein 
response (ER UPR), and the mitochondrial UPR (UPRmt). 
The apparent function of ATF5 in these responses is to 
mediate transcription of molecular chaperones, proteases, 
and prosurvival proteins. From this, a simplified model for 
the role of ATF5 in stress responses can be diagrammed 
as seen in Figure 1. This Figure exemplifies the function 
of ATF5 in stress responses where ATF5 is upregulated 
as transcriptional initiation shifts away from inhibitory 
uORFs as a component of the ISR [6]. ATF5 can then 
activate transcription of molecular chaperones and 
proteases which are involved in restoring proteostasis [30, 
31]. If proteostasis is significantly imbalanced, apoptosis 
can then be triggered by downregulation of ATF5 [25, 32]. 
It is likely that this prosurvival effect is due to regulation 
of heat shock proteins and antiapoptotic proteins such as 
HSP27 [31], BCL-2 [33], and MCL-1 [34], as detailed 
in the sections below. As most of the mechanistic studies 
involved with the prosuvival function of ATF5 were done 
in cancer cells, the mechanism with which ATF5 mediates 
a prosurvival effect in normal tissues remains to be 
characterized.
ER UPR and cytosolic heat shock response
Two specific yet somewhat overlapping cellular 
responses to stress are the ER UPR and the cytosolic 
heat shock response. Here, accumulation of misfolded 
proteins in either the ER or cytosol results in upregulation 
of chaperones and proteases involved in resolving 
improper protein folding. Proteasome inhibition and 
ER stress upregulate ATF5 via PERK-mediated eIF2α 
phosphorylation, which then results in a decrease in global 
protein translation and a shift in translational control 
away from an inhibitory upstream open reading frame 
(uORF) [6]. This upregulation of ATF5 can then lead to 
transactivation of HSP27, a molecular chaperone critical 
in promoting survival and proper protein folding, in 
response to aberrant protein folding within the cytosol and 
the ER [31, 35, 36]. In addition, HSP70 has been found 
to increase ATF5 protein stability, which suggests ATF5 
functions to control cell fate in response to perturbations 
in proteostasis in the context of the cytosolic heat shock 
response [37]. It was found that in growth plate cartilage 
the bZip transcription factor BBF2H7 mediates a 
prosurvival effect in response to ER stress by activating 
the ATF5-MCL1 pathway [38]. The prosurvival function 
Oncotarget84598www.impactjournals.com/oncotarget
of ATF5 in response to ER stress was also seen in cultured 
adult neurons treated with the ER stress-inducing agent 
tunicamycin [25]. In this study tunicamycin was shown 
to selectively elicit profound transcriptional activation of 
genes involved in ER UPR but not mitochondrial UPR, 
suggesting this response is ER UPR-specific. It was also 
found that ATF5 regulates and is regulated by the ER 
stress-responsive and fate-determinative transcription 
factor CHOP, thereby giving further evidence that ATF5 
interacts with signaling pathways involved in ER stress 
responses and cell survival [39, 40]. Overall, it appears 
that ATF5 is not only involved in mediating cell survival 
in the context of the cytosolic heat shock response and 
ER stress but also initiating transcriptional responses to 
resolve these perturbations in proteostasis. 
Pancreatic β-cells and ER stress
Within the pancreatic islets lie β-cells which 
are critical to maintaining insulin levels and energy 
anabolism. These β-cells are especially susceptible to 
many stressors, including ER and oxidative stress, and 
their ability to resolve these perturbations determines 
their survival [41]. Initially, it was found that ATF5 is 
a likely downstream target of the transcription factor 
PDX1, which mediates β-cell susceptibility to ER stress 
[42]. Further research by Juliana et al. reported that 
β-cells induced ATF5 expression upon induction of ER 
stress, and that knockdown of ATF5 made these cells 
susceptible to ER stress-induced apoptosis via hindered 
inhibition of global protein translation [32]. While this 
is true, the physiological relevance of ATF5 activity to β 
cell function is unclear since in this study ATF5 knockout 
mice showed no alteration in their glucose homeostasis 
phenotype in glucose and insulin tolerance tests. However, 
β-cell apoptosis was increased in ATF5 knockout mice. 
Additional studies revealed that ATF5 binds to the 
promoter and upregulates the protein TXNIP, which is 
involved in coupling ER stress-inflammasome signaling 
and regulates β-cell survival, therefore indicating that 
ATF5 may facilitate crosstalk between ER stress and 
inflammatory pathways [43]. Overall, these findings 
indicate that ATF5 plays a critical role in regulating β-cell 
survival in response to ER stress and indicates that ATF5 
may contribute to β-cell dysfunction in diseases such as 
diabetes mellitus.
Mitochondrial UPR
With much of the past research focused on 
evaluating the role of ATF5 in ER stress, a more recent 
study revealed the importance of ATF5 in mitochondrial 
Figure 1: Role of ATF5 in cellular stress responses. ATF5 is upregulated by various stressors, which then results in subsequent 
activation of molecular chaperones, proteases, and prosurvival molecules. Downregulation of ATF5 drives apoptosis in these cells. Image 
was generated using ChemBioDraw Ultra 14.0 (UC Davis License) and PowerPoint 2013.
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stress. Mitochondria possess their own unfolded protein 
response (UPRmt) that is initiated upon accumulation of 
unfolded protein within the mitochondrial matrix, thereby 
activating CHOP and C/EBPβ to regulate expression of 
mitochondrial stress genes [44]. Analysis of autosomal 
dominant ataxia patients, characterized by mutation in 
a mitochondrial protease gene, showed a significant 
induction of ATF5, thus suggesting ATF5 is induced by 
mitochondrial stress [45]. A recent study by Fiorese et al. 
showed that ATF5 has many parallel functions relative 
to the transcription factor ATFS-1 that mediates UPRmts 
in C. elegans. In this study, it was shown that ATF5 can 
recapitulate the UPRmt in ATFS-1 KO C. elegans by 
upregulating genes involved in resolving UPRmts such 
as mitochondrial chaperones and proteases [30]. Fiorese 
et al. reported the presence of a mitochondrial targeting 
sequence (MTS) within ATF5 and that in C. elegans 
ATF5 localizes to mitochondria in the absence of stress 
and moves to the cytosol/nucleus during mitochondrial 
stress, thereby indicating that ATF5 mediates UPRmt via 
organelle partitioning. Lastly, Fiorese et al. reported that 
in mammalian cells ATF5 mediates maintenance and 
recovery of mitochondrial function after induction of 
UPRmt by regulating cell viability and transcription of 
mitochondrial chaperones and proteases. These chaperones 
and proteases include HSP60, mtHSP70, and LONP1. 
While this research provides a novel function for ATF5 
in cellular stress responses, it imposes further curiosity 
whether the UPRmt processes mediated by ATF5 can 
contribute to cancer development in ATF5-dysregulated 
cancers [46]. With this in mind, ATF4 has also been shown 
to regulate mitochondrial stress responses [7] and ATF4 
and ATF5 are paralogs of ATFS-1. Therefore, the function 
of ATFS-1 in C. elegans may represent the activity of both 
ATF4 and ATF5 [47].
Role of ATF5 in the development of a diverse range of 
cancers
With the role of ATF5 in promoting survival 
in normal cells established [31, 33, 37], it could be 
hypothesized that dysregulation of ATF5 may serve as 
a survival factor in cancer. Indeed, upon analyzing the 
expression levels of ATF5 in a variety of cancer types it 
is evident that ATF5 expression is highly upregulated in 
various forms of cancer such as glioma, breast cancer, lung 
cancer, and numerous others. This suggests an oncogenic 
role for ATF5 in these cancer types where overexpression 
is seen in malignant tissues. The oncogenic functions 
for ATF5 are outlined in Figure 2, where ATF5 has been 
shown to promote cell survival, migration, radioresistance, 
and amino acid synthesis while inhibiting autophagy. It 
could be hypothesized that these functions mediated by 
ATF5 in cancer also occur in nontransformed cells, but 
this hypothesis has yet to be tested. ATF5 expression is 
also significantly associated with tumor grade in several 
cancer types [48, 49]. In addition to these functions is 
the novel role for ATF5 as a structural protein where it 
facilitates formation of the centrosome, thereby suggesting 
ATF5 may promote proper mitotic function [50]. Although 
this is intriguing, no studies have been conducted 
assessing whether ATF5 promotes cancer development via 
its centrosomal function. Another interesting property for 
ATF5 in cancer is seen in hepatocellular carcinoma where 
ATF5 appears to possess a tumor suppressor role [51].
Glioma
Of the cancers with which the role of ATF5 has 
been investigated, gliomas have been the most extensively 
studied. Initial expression profiling of glioblastoma 
(GBM) revealed ATF5 expression was inversely correlated 
with overall patient survival, indicating the importance of 
ATF5 expression to patient outcomes in the clinic [34, 
52]. ATF5 expression was also shown to be upregulated 
in GBMs and anaplastic gliomas relative to low grade 
gliomas and normal cortical tissue, indicating that ATF5 
expression may be associated with more malignant glioma 
phenotypes [53]. Indeed, analysis of ATF5 promoter 
methylation in glioma revealed that there is a substantial 
decrease in promoter methylation in high grade gliomas 
relative to low grade gliomas and normal tissue, thereby 
suggesting alterations in promoter methylation drive 
aberrant ATF5 expression in high grade gliomas [49]. 
In addition, ATF5 was shown to mediate the survival 
response to serum deprivation and staurosporine treatment 
in C6 glioma cells supporting the notion that ATF5 has an 
oncogenic and prosurvival role in gliomas [33]. 
Interference with ATF5 function by transient 
transfection of a dominant-negative elicited an apoptotic 
response in glioma cell lines but spared astrocytes, 
though astrocytes ectopically expressing dnATF5 exited 
the cell cycle [54]. Further studies were performed 
using a tetracycline-inducible Tet-off mouse model 
to induce expression of dnATF5 driven by a GFAP 
promoter, and retrovirally-induced brain tumors were 
shown to be regressed and prevented by doxycycline 
withdrawal [27]. These results led to the development 
of a systemically deliverable dnATF5 peptide fused to 
a penetratin motif to allow for extracellular entry [55, 
56]. A recombinant FLAG-tagged version of this peptide 
was shown to effectively cross the blood-brain barrier 
after IP injection, elicit apoptosis within the tumors, 
and fully eradicate virally-induced brain tumors [55]. A 
chemically synthesized variant of this dominant-negative 
peptide, termed CP-d/n-ATF5-S1, was shown to elicit a 
significant apoptotic response in culture and inhibit growth 
of treatment-resistant glioblastoma xenografts, though 
tumor regression was not observed [56]. These findings 
point to the significance of ATF5 in the development of 
gliomas and suggest that ATF5-targeted therapy is a viable 
treatment option for glioblastoma, which is one of the 
deadliest forms of cancer and is characterized by a dismal 
prognosis [57].
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The mechanisms which ATF5 promotes cell 
survival have been well studied in gliomas relative to 
other cancer types. For example, Karpel-Massler et al. 
showed that interference with ATF5 activity by CP-d/n-
ATF5-S1 administration downregulated the antiapoptotic 
proteins BCL2 and MCL1, though it is suggested that 
downregulation of these proteins is mediated by effects 
on the deubiquitinase Usp9x [56]. The proposed paradigm 
is that Usp9x stabilizes the antiapoptotic proteins BAG3, 
MCL1, and BCL2, and that CP-d/n-ATF5-S1 mediates 
downregulation of Usp9x, thereby leading to an apoptotic 
response. This is further supported by findings that Usp9x 
knockdown recapitulated the apoptotic effects of CP-
d/n-ATF5-S1 and also led to downregulation of BAG3, 
MCL1, and BCL2 in various glioblastoma cell lines [56]. 
Though this is true, no experiments have been conducted 
to evaluate whether the effect of CP-d/n-ATF5-S1 on 
USP9X is ATF5-specific, and as can be seen in Figure 3, 
the anticancer mechanism of dnATF5 can be attributed to 
disruption of ATF5 homodimers, heterodimers, or ATF5-
associating bZip homo/heterodimers. Li et al. reported 
that in C6 glioma cells ATF5 activated transcription of 
BCL2 in an ATF5-specific response element (ARE)-
dependent fashion, though no ChIP assays were performed 
to assess direct promoter binding [33]. Contrary to these 
results, Sheng et al. reported that BCL2 expression is 
not regulated by ATF5 but that ATF5 binds directly to 
the promoter of MCL1 to activate its transcription [34]. 
While these results confound one another, the activity of 
ATF5 in a cell is highly dependent on coexpression with 
associating transcription factors. Therefore, the effect of 
ATF5 knockdown can be highly cell type-dependent and 
could therefore explain why BCL2 seems to be regulated 
by ATF5 in some glioblastoma cell lines but not in others. 
Lastly, Li et al. reported that the molecular 
chaperone HSP70 was found to stabilize ATF5 protein 
by physical interaction with the N-terminal proline rich 
portion of ATF5 [37]. HSP70-mediated stabilization of 
ATF5 led to increased ATF5 activity and transcription of 
downstream ATF5 targets such as BCL2. This reveals an 
important post-translational mechanism with which cancer 
cells can aberrantly upregulate ATF5 activity by increasing 
the half-life of ATF5.
Breast carcinoma
Most of the work on ATF5 in relation to breast 
cancer has focused on ATF5-mediated promotion of cell 
survival, though studies have been conducted analyzing 
ATF5-mediated invasive characteristics. Monaco et 
al. reported a significant upregulation of nuclear ATF5 
expression in breast cancers relative to paired normal 
breast tissue with a significant upregulation taking place 
in invasive ductal, invasive lobular, in situ ductal, and in 
situ lobular carcinomas [58]. Analysis revealed there was 
no correlation between ATF5 expression and marker status 
i.e. ER/PR and HER2/neu. It was also shown by Monaco 
et al. that upon interference with ATF5 function via use 
of dnATF5 transgene, breast cancer cell lines underwent 
apoptosis while nonneoplastic cell lines were spared of 
this effect. Dluzen et al. showed that in a breast cancer 
cell line, in response to apoptotic triggering mechanisms 
of serum deprivation and staurosporine treatment, ATF5 
Figure 2: Oncogenic roles for ATF5 in the promotion of cancer. ATF5 is dysregulated in a variety of cancer types and is 
associated with effects on cell migration, amino acids synthesis, radioresistance, and cell survival while inhibiting autophagy. ATF5 is also 
associated with tumor pathology where ATF5 expression is positively correlated with tumor grade. Image was generated using PowerPoint 
2013.
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was downregulated. Conversely, forced ATF5 expression 
blocked apoptosis resulting from serum deprivation 
and staurosporine treatment. These data suggest that 
ATF5 acts as an anti-apoptotic transcription factor in 
breast cancer [33]. This study also reported that ATF5 is 
responsible for the transactivation of BCL-2 via an ATF5-
specific regulatory element, and that this is predominantly 
responsible for the cell-type dependent antiapoptotic 
function of ATF5 in breast cancer. Also shown in parallel 
with glioma, ATF5 activated expression of the early 
growth response factor 1 (EGR-1) gene in a breast cancer 
cell line via a novel ATF5 DNA regulatory element [59]. 
These results give preliminary in vitro data supporting 
ATF5 as a potential target for treatment of breast cancers, 
but detailed in vivo studies probing the function of ATF5 
in breast cancer have yet to be performed.
A recent study by Nukuda et al. reported that ATF5 
correlated with invasive capability of breast cancer cell 
lines, and that siRNA knockdown of ATF5 reduced the 
invasiveness of these cells [60]. In addition, it was shown 
that ATF5 knockdown resulted in reduced spindle-
like morphology and expression of integrins α2β1. 
These findings indicate that while ATF5 may function 
to promote cell survival in breast cancer, it may also 
function to promote metastasis by regulating the invasive 
characteristics of breast carcinomas. Further studies 
composed of in vivo and clinical studies would help 
better evaluate the role of ATF5 in regulating the invasive 
characteristics of breast cancers.
Leukemia and lymphoma
The importance of ATF5 in the development of 
leukemia first became evident during analysis of its role 
in the survival of myeloid progenitor cells. It was found 
that upon IL-3 deprivation, myeloid progenitor cells 
underwent apoptosis and subsequent gene expression 
profiling revealed ATF5 as the most highly downregulated 
gene [61]. Ectopic expression of ATF5 inhibited the 
apoptotic response induced by IL-3 deprivation [62]. 
Sheng et al. reported that BCR-ABL induces ATF5 
expression through the PI3K/AKT/FOXO4 pathway, and 
that ATF5 binds directly to the promoter of mTOR to 
activate its transcription [63]. In addition, this activation 
of mTOR suppressed autophagy and it was shown that 
imatinib treatment induced autophagy at least in part by 
downregulating ATF5 and the downstream mTOR. These 
Figure 3: Proposed mechanisms for dnATF5 anticancer activity. dnATF5 is thought to disrupt ATF5 homo/heterodimerization 
or homo/heterodimerization of two non-ATF5-interacting bZip transcription factors. This results in USP9x-mediated destabilization of 
antiapoptotic proteins or inhibition of ATF5-mediated transactivation of BCL2, MCL1, BAX, mTOR, and asparagine synthetase, thereby 
leading to apoptosis. Image was generated using CellDesigner 4.4 and PowerPoint 2013.
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findings suggest that ATF5 expression is a critical mediator 
of autophagic death in BCR-ABL chronic myelogenous 
leukemias in response to imatinib treatment.
Several studies have reported the significance of 
ATF5 activity to clinical outcomes in leukemia patients 
[64, 65]. Mittal et al. analyzed samples from chronic 
lymphocytic leukemia (CLL) patients harboring 11q 
and trisomy 12 chromosomal aberrations and found that 
these patients had significantly higher expression of ATF5 
relative to CLL patients with normal karyotype or 13q 
deletion [65]. It was also found that these patients with 
higher ATF5 expression had significantly worse clinical 
outcomes in the context of time to first treatment. 
Rousseau et al. reported that in childhood acute 
lymphoblastic leukemia (ALL), polymorphisms in the 
5′UTR of the ATF5 transcript altered the expression of 
ATF5 and were also associated with event free survival 
of childhood leukemia patients [64]. Since ATF5 has 
been shown to regulate asparagine synthetase expression, 
and asparaginase is a common treatment in childhood 
ALL, it is possible that interfering with ATF5 pathways 
in combination with asparaginase treatment could yield 
better patient outcomes.
Follicular lymphoma (FL), characterized by slow 
disease progression, often undergoes transformation to 
aggressive diffuse large B-cell lymphomas (DLBCL) [66]. 
Bisikirska et al. analyzed gene expression data using the 
Master Regulator Inference Algorithm (MARINa) and 
identified ATF5 as one of several transcription factors 
responsible for transformation of FLs to DLBCLs [66]. This 
study also found that ATF5 was significantly upregulated 
in DLBCL compared to FL and that knockdown of ATF5 
partially restored the FL expression signature in DLBCL 
cell lines. These findings suggest that ATF5 expression may 
be a valuable prognostic marker in lymphomas and that 
targeting ATF5 or ATF5-mediated pathways may provide 
therapeutic benefit to patients with DLBCLs.
Lung carcinoma
Previous research by Ishihara et al. has helped 
clarify the role of ATF5 in the promotion of lung cancer 
via modulating the growth and invasiveness of A549 lung 
carcinoma cells [67]. Ishihara et al. showed that A549 cells 
with stable ATF5 transfection were resistant to gamma 
irradiation and that ATF5 expression was highest during 
the G1/S transition through the cell cycle. A549 cells were 
exposed to gamma irradiation at different times post-cell 
cycle synchronization and cells at the G1/S boundary 
exhibited higher radioresistance, thereby indicating that 
radioresistance correlates with cell cycle-dependent 
expression of ATF5. Cyclin levels of ATF5 transfected 
cells were also significantly altered, with cyclin A2 being 
upregulated and cyclin E1 downregulated. This, together 
with an enhanced growth rate in vitro and in vivo of ATF5-
transfected cells, suggests ATF5 promotes cell cycle 
progression and growth of lung carcinomas. 
Ishihara et al. also looked at the effect ATF5 has on 
the invasive phenotype of A549 cells. ATF5-transfected 
A549 cells showed an enhanced migratory phenotype with 
ATF5 siRNA knockdown abrogating this promigratory 
effect. This promigratory effect of ATF5 was also shown 
to be reliant on ATF5-dependent induction of β1 integrin. 
In addition to ATF5 modulating growth and invasiveness 
of a lung cancer cell line, Ishihara et al. analyzed clinical 
lung cancer data from various cancer genome databases 
and showed that ATF5 expression correlated well with 
overall patient survival. Therefore, ATF5 is suggested 
to facilitate lung cancer development by promoting 
cellular proliferation and radioresistance while also being 
associated with poorer patient prognosis. It would be 
interesting to know if the expression levels of ATF5 in the 
ATF5-transfected A549 cells in this study are comparable 
to expression levels in clinical lung carcinoma samples.
Lastly, Fernandez et al. show via global gene 
expression analysis that loss of the tumor suppressor 
LKB1/STK11 leads to significant upregulation of ATF5 in 
primary lung carcinomas [68]. Though this is intriguing, 
the role that ATF5 plays in promoting LKB1/STK11 
mutant lung carcinomas is unknown. 
Ovarian carcinoma
Chen et al. analyzed clinical samples of epithelial 
ovarian carcinomas for ATF5 expression and saw a 
significant upregulation of ATF5 compared to benign 
and normal ovarian tissue, with ATF5 expression also 
correlating to cancer stage [69]. In addition, interference 
with ATF5 activity by transient transfection of dnATF5 
elicited a substantial apoptotic response that was 
accompanied by a downregulation in BCL2 expression. 
There was no investigation into whether BCL-2 
downregulation was responsible for the apoptotic effect 
and whether there were any ATF5-independent effects of 
the dnATF5.
Pancreatic carcinoma
ATF5 expression has been confirmed in pancreatic 
cancer cell lines and significant upregulation is seen 
in primary tumors relative to normal pancreatic tissue, 
suggesting a role for ATF5 in the development of 
pancreatic cancer [70]. Hu et al. investigated the role that 
ATF5 plays in mediating pancreatic cancer resistance to 
paclitaxel chemotherapy. It was shown that interfering 
with ATF5 function by use of a dnATF5 protein elicited a 
significant apoptotic response in SW1990 pancreatic cells, 
and that combination treatment with paclitaxel further 
enhanced paclitaxel-induced apoptosis. In addition, ATF5 
was shown to induce and inhibit promoter activity of 
BCL-2 and BAX, respectively, with ectopic expression of 
ATF5 also abrogating paclitaxel-induced downregulation 
of the BCL-2 promoter. These findings suggest that the 
activity of ATF5 mediates survival of pancreatic cancers 
via regulation of BCL-2 and BAX, and that interference 
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with ATF5 activity potentiates apoptosis mediated by 
paclitaxel treatment. While this is significant, the studies 
were performed with a single cell line and therefore more 
studies need to be conducted to establish the association 
between ATF5 activity and clinical presentations of 
pancreatic cancer.
Karpel-Massler et al. evaluated the effect of a 
synthetic cell-penetrant variant of dnATF5 (CP-d/n-
ATF5-S1) on the growth of a diverse panel of treatment 
resistant cancers, including the PANC-1 pancreatic 
carcinoma cell line [56]. These cells elicited a robust 
in vitro response to CP-d/n-ATF5-S1 administration, 
showing a significant dose-dependent decrease in cell 
viability and increase in apoptosis. Notably, at the highest 
dose of CP-d/n-ATF5-S1 the early apoptotic response in 
PANC-1 cells reached over 60% of the cell population 
while late apoptosis/necrosis consisted of about 20%. The 
antiapoptotic proteins MCL-1 and BCL-2 were also shown 
to be significantly downregulated upon administration of 
CP-d/n-ATF5-S1 in a concentration-dependent fashion. 
The proapoptotic effect of BH3 mimetics, with which 
MCL-1 mediates apoptotic resistance, was shown to be 
significantly augmented by combination treatment with 
CP-d/n-ATF5-S1. Interestingly, the growth of PANC-
1 xenografts in the flank of mice were not significantly 
altered in response to intraperitoneal CP-d/n-ATF5-S1 
treatment while many other tumor types showed significant 
growth reduction. There was no subsequent investigation 
into the reason for this lack of response, and reduced in 
vivo tumor uptake of CP-d/n-ATF5-S1 was not evaluated.
Rectal carcinoma
Though little is known about the role of ATF5 in 
the development of rectal carcinomas, Kong et al. showed 
that ATF5 protein levels are significantly upregulated in 
rectal carcinomas relative to normal rectal tissues [48]. 
Interestingly, in this study ATF5 mRNA levels between 
neoplastic and nonneoplastic tissues were not significantly 
different, therefore indicating that upregulation of ATF5 
protein levels are likely mediated via post-transcriptional 
mechanisms in rectal cancers [48]. Additionally, positive 
ATF5 staining was significantly associated with poorly 
differentiated rectal tumors relative to moderate-well 
differentiated tumors [48]. These findings indicate ATF5 
plays a role in the development of rectal cancers and that 
high expression of ATF5 is associated with greater tumor 
grade.
Renal cell carcinoma
ATF5 expression has been confirmed in a variety of 
renal cell carcinoma (RCC) cell lines and ATF5 expression 
was shown to be significantly upregulated in RCC tissues, 
though these results were limited by the fact the researchers 
only tested a single nonneoplastic kidney cell line [71]. In 
patient-derived RCC tissue sections, only a third of tissues 
tested stained positive for ATF5 and there was no significant 
difference in ATF5 expression compared to nonneoplastic 
renal tissue [58]. This would suggest ATF5 may not play 
a significant role in aiding the development of renal cell 
carcinomas. Conversely, Morris et al. identified ATF5 
as a candidate tumor suppressor gene through epigenetic 
analysis of differential gene expression in RCC cells treated 
with a demethylating agent [72]. ATF5 was significantly 
upregulated in several RCC cell lines after DNA 
demethylation, indicating a potential tumor suppressor role 
for ATF5 in RCC, perhaps similar to the role of ATF5 in 
hepatocellular carcinoma. Upon a more extensive analysis 
of RCC cell lines, it was shown that ATF5 expression was 
not consistently silenced epigenetically, therefore indicating 
that ATF5 is likely not a putative tumor suppressor in RCC. 
Hepatocellular carcinoma
Contrary to the oncogenic role of ATF5 in 
glioblastoma and other previously discussed malignancies, 
ATF5 appears to elicit a tumor suppressive role in 
hepatocellular carcinomas (HCCs). It has been reported 
that expression levels of ATF5 were significantly reduced 
in HCC relative to paired nonneoplastic hepatic tissue 
[51, 73]. ATF5 expression in HCC was also significantly 
associated with intrahepatic metastasis and liver cirrhosis, 
although there are mixed results pertaining to liver 
cirrhosis. Gho et al. showed that upon ectopic expression 
of ATF5, various HCC cell lines exemplified hindered 
growth up to 50% compared to controls with apoptosis 
ruled out as a confounding factor [51]. This effect on 
growth inhibition was reportedly due to cell cycle arrest at 
the G2-M phase of the cell cycle. Analysis of downstream 
targets of ATF5 via differential gene expression analysis 
revealed the helix-loop-helix protein ID1 as a target 
of ATF5 and mobility shift assays showed ATF5 binds 
to a cyclic AMP response element (CRE) within the 
promoter of ID1. Consistent with the repressive role of 
ATF5 at CREs, ATF5 expression was shown to inversely 
correlate with ID1 expression. Investigation into the 
mechanism of ATF5 downregulation in HCC indicated 
that DNA mutations, promoter methylation, histone 
modifications, and gene copy loss are all responsible for 
loss of ATF5 expression. Liu et al. reported that NPM1, a 
nucleolar chaperone, destabilizes ATF5 and that ectopic 
NPM1 expression abrogates ATF5-mediated effects on 
downstream targets in Hep3B cells [74]. In addition, the 
G2-M arrest and reduction in cell viability attributed to 
ectopic ATF5 expression was abrogated by co-expression 
with NPM1 in Hep3B cells. Wu et al. analyzed the 
prognostic significance of ATF5 expression in HCC, and 
found that high ATF5 expression was associated with 
recurrence-free survival in HCC hepatectomy patients 
but not overall survival [73]. Lastly, Gao et al. analyzed 
HCC samples paired to nonneoplastic hepatic tissue for 
differentially expressed- and methylated genes [75]. It was 
found that ATF5 promoter methylation was substantially 
increased in HCC and that ATF5 knockdown enhanced 
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growth of various HCC cell lines, further supporting the 
tumor suppressive role of ATF5 in HCC.
Converse to the reported tumor suppressor role of 
ATF5 in HCC, Xu et al. report that ATF5 expression is 
regulated by miR-148a via decreased activation of the 
AKT/FOXO4/ATF5 pathway in HepG2 cells [76]. In 
addition, it was shown that ATF5 knockdown resulted in 
reduced mTOR protein levels. These findings suggest that 
although ATF5 inhibits the growth of HCC, it may still 
have the potential to possess an oncogenic role based on 
increased stimulation of AKT/mTOR pathways.
Interference with ATF5 activity as a therapeutic 
strategy
As mentioned in the previous section on the 
role of ATF5 in cancer development, ATF5 possesses 
numerous properties that make it an attractive target for 
cancer treatment. The role of ATF5 in the transcriptional 
activation of proteins such as mTOR, BCL2, and MCL1 
shows the importance of ATF5 in modulating activity of 
pathways critical to the development of cancer. Though 
this is true, ATF5 is a transcription factor and therefore is 
unlikely to be targetable via conventional small molecule 
targeting approaches. Initial use of a dominant-negative 
was developed as an experimental tool to modulate ATF5 
activity in differentiation studies with neural progenitors 
[15]. The structure of this dominant-negative, termed 
Azip, is similar to that of WT ATF5 except the N-terminal 
portion is removed. This N-terminal portion includes the 
DNA-binding domain and acidic activation domain, thus 
eliminating the ability of this peptide to bind to DNA and 
participate in activation of transcription. This resulted 
in a dominant-negative protein that, in theory, binds to 
ATF5 and ATF5 binding partners to hinder their activity, 
but cannot partake in direct DNA binding. In addition, a 
region was added to the N-terminal portion of the protein 
called the enhanced leucine zipper which is composed of 
an acidic α-helix with leucines at every seventh residue. 
This enhanced leucine zipper has the potential to form 
salt bridges with the basic DNA binding domain of 
WT ATF5 or binding partners, thereby facilitating the 
intermolecular interactions between dnATF5 and WT 
ATF5. The C-terminal extended valine zipper region 
of ATF5 was also removed in order to reduce peptide 
aggregation [77]. 
Further work led to the development of an Azip 
protein fused to a cell-penetrant protein, specifically 
a penetratin motif, thus allowing passage through the 
blood-brain barrier and extracellular entry into tumors 
upon systemic injection [55, 56, 78]. Two variants of 
this penetratin-fused dominant-negative were developed: 
a recombinant variant with a FLAG tag termed CP-d/n-
ATF5-RP, and a synthetic variant termed CP-d/n-ATF5-S1. 
A structural comparison of WT ATF5, Azip, CP-d/n-ATF5-
RP, and CP-d/n-ATF5-S1 can be seen in Figure 4. 
Figure 4: Comparison of WT ATF5 with dnATF5 Variants. WT ATF5 contains a basic DNA binding domain adjacent to the 
leucine zipper domain. The first generation of dnATF5, i.e. Azip, was about a third of the molecular weight of WT ATF5, and had the 
N-terminal portion and the DNA binding domain removed, accompanied by an acidic enhanced leucine zipper and an N-terminal FLAG 
tag. This further led to the development of recombinant ATF5 which had the C-terminal portion of Azip removed and included the addition 
of an N-terminal penetratin motif. The synthetic variant of this cell-penetrant dnATF5 protein was further modified by removal of the FLAG 
tag and a segment of residual vector-derived amino acids. Image was generated using PowerPoint 2013 [80].
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Future directions
The literature discussed in this review provides a 
foundation for the functional role of ATF5 in the context 
of cellular differentiation, stress, and cancer. Further 
studies would be useful in building upon this foundation. 
For example, utilizing conditional knockout models would 
be paramount to concluding the tissue-specific effects on 
differentiation mediated by ATF5. In addition, determining 
whether the functions of ATF5 in mitochondrial stress and 
the UPRmt are relevant to cancer development would be 
critical toward elucidation of ATF5 function in cancer.
Developments in ATF5-targeted biologic therapies 
have resulted in the opening of an interesting new field of 
study. Here, small (< 10 kDa) dnATF5 peptides are injected 
systemically to elicit interference with ATF5 activity. 
Further advancements with this technology could include 
modifying the structure of the dominant-negative protein, 
such as altering the molecular weight or paying special 
attention to peptide sequences susceptible to proteolytic 
cleavage, to enhance the anticancer properties of this 
biologic. Altering the molecular weight of the peptide 
may alter its ability to cross cell membranes, therefore 
altering its distribution and clearance, whereas reduced 
proteolytic cleavage may result in decreased systemic 
elimination. In addition, studies should be performed to 
validate that dnATF5 is indeed targeting ATF5 and that the 
responses seen are not from an ATF5-independent action. 
The success of systemically deliverable dnATF5 peptides 
suggests this paradigm could be used in the development 
of therapeutic peptides targeting a wide variety of bZip 
transcription factors, such as AP-1. Further, a recent study 
by Huang et al. describes a novel approach to targeting 
ATF5 where apolipoprotein E3 high density lipoprotein is 
loaded with siRNA and calcium phosphate, and delivered 
to glioblastoma xenografts in vivo to inhibit tumor growth 
[79]. This also suggests gene therapy routes may be 
attractive delivery methods for ATF5-targeted therapies.
Previous studies show that ATF5 regulates neural 
stem cell differentiation and also cell fate in response 
to stress in adult neurons. Therefore, additional toxicity 
studies should be conducted to establish how dnATF5 
administration may alter neural differentiation and 
survival of adult neurons. 
CONCLUSIONS
Dysregulation of ATF5 expression is commonly 
observed in a variety of different cancer types such as those 
of the brain, lung, and pancreas. Recent research has started 
to reveal the role of ATF5 in modulating various oncogenic 
characteristics such as evasion of apoptosis, tissue invasion, 
and deregulation of cellular bioenergetics. The critical role 
for ATF5 in the development of various cancer types has led 
to preclinical evaluation of several methods to target ATF5 
and has yielded promising results. Future preclinical and 
clinical research will help reveal whether ATF5 is indeed a 
viable target for clinical cancer therapy. 
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